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Foxp3+ regulatory T (T reg) cells are important for the es-
tablishment of immunological tolerance. Several independent 
studies originally demonstrated that a strong-agonistic ligand 
provided under subimmunogenic conditions results in effi-
cient conversion of naive CD4+ T cells into Foxp3+ T reg 
cells (Kretschmer et al., 2005; Daniel et al., 2010; Gottschalk 
et al., 2010; Bilate and Lafaille, 2012).
We have previously reported that a strong-agonistic 
variant of a weak-agonistic insulin epitope provided under 
appropriate subimmunogenic conditions conferred efficient 
insulin-specific T reg cell induction in nonobese diabetic 
(NOD) mice (Daniel et al., 2011). Despite this, and given 
our growing appreciation regarding the complexity and het-
erogeneity of immune activation processes in type 1 diabetes 
(T1D; von Herrath et al., 2016), it appears reasonable to argue 
that T reg cell induction per se cannot be equated to efficacy 
of T1D prevention in NOD mice.
In the study by Bergman et al., the application of the 
weak-agonistic insulin B:9-23 peptide (Stadinski et al., 2010) 
promotes significant disease worsening, suggesting that ther-
apeutic application of such an approach during ongoing islet 
autoimmunity can be prone to undesired consequences.
Given a setting prone to autoimmune activation as in 
T1D, one important challenge for efficient T reg cell conver-
sion is to maintain appropriate subimmunogenic conditions, 
which are critically influenced by antigen dose and activation 
status of antigen-presenting cells and T cells (Haxhinasto et 
al., 2008; Sauer et al., 2008) as well as by intrinsic T cell sen-
sitivity to antigenic stimulation. Although we agree that the 
selection of a 5 µg/day insulin peptide dose was a reason-
able starting point to attempt T1D prevention in NOD mice, 
analyses of T cell–related vaccination responses (biomarkers 
of vaccination efficacy [Rekers et al., 2015]) would have 
helped to understand whether in the present experimental 
setup by Bergman et al. (2017) the insulin therapy was indeed 
tolerizing. Accordingly, it has been proposed that efficient T 
reg cell induction requires individual optimizations of ligand 
dose in a given experimental environment (Kretschmer et 
al., 2005; Gottschalk et al., 2010) and is supported by the 
assessment of naive versus activated CD4+ T cells before an-
tigen application because activated CD4+ T cells are resistant 
to Foxp3+ T reg cell conversion. Therefore, the observation by 
Bergman et al. (2017) that already the weak-agonistic insu-
lin B:9-23 peptide promotes a disease worsening might sug-
gest that in these experimental conditions the overall setting 
might be predisposed to immune activation besides the auto-
immune NOD phenotype per se.
Concerning antigen application by osmotic mini-pumps, 
in our previous study, control animals were not left unma-
nipulated, as erroneously assumed by Bergman et al. (2017), 
but were implanted with pumps filled with vehicle to match 
treatment conditions. For all groups, the pumps remained 
longer than 2 wk in the animals but were not left in place 
for the full length of the experiment (40 wk). Instead, for all 
groups, the pumps were explanted after a total time of 4 wk 
by aseptic surgery. The fact that in our previous study NOD 
mice implanted with vehicle filled pumps (controls) as well as 
animals treated with the weak-agonistic insulin peptide B9:23 
were not protected from disease excludes a protective effect 
of “pump-induced inflammation.”
We agree with Bergman et al. (2017) that in addition 
environmental factors might critically contribute to study 
outcomes and prevention efficacy. Bergman et al. (2017) used 
NOD mice originally obtained from The Jackson Laboratory. 
To study diabetes prevention after insulin-specific tolerogenic 
vaccination, we had previously used NOD mice obtained 
In this issue of JEM, Bergman et al. (https ://doi .org /10 .1084 /jem .20160471) challenge the data published in our previous JEM 
paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we 
provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3+ 
regulatory T cell conversion.
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from Taconic and offspring of these Taconic-derived NOD 
animals bred at our local animal facility.
Currently, the exact contribution of the origin of NOD 
mice, whether from The Jackson Laboratory or Taconic, in 
affecting tolerance induction and efficacy of disease interven-
tion remains unclear. Despite this, careful studies have recently 
compared gut microbiota between colonies of NOD mice 
derived from NOD/Jackson and NOD/Taconic. Microbi-
ota composition revealed major differences on genus level 
and much more diverse microbiota in NOD/Taconic mice. 
More recent data support the notion that specific species 
within microbiota, e.g., Akkermansia muciniphila, Allobac-
ulum, and Mucispirillum, carry diabetes-delaying and im-
mune-modulating properties (Hansen et al., 2012). Bergman 
et al. (2017) describe the presence of segmented filamentous 
bacteria (SFB) in their study colony. Recent findings sug-
gest that SFB boost and exacerbate autoimmune activation 
by promoting differentiation and migration of Peyer’s patch 
T follicular helper cells, e.g., in autoimmune arthritis (Teng 
et al., 2016). Therefore, evidence that specific elements of the 
microbiota impinge on peripheral T reg cell induction (Lath-
rop et al., 2011) and on autoimmune activation is beginning 
to emerge (Mathis and Benoist, 2012; Pearson et al., 2016) 
and could also contribute to the observed different outcomes 
between the two studies discussed here.
Bergman et al. (2017) used the analysis of insulin auto-
antibodies to assess autoimmune activation in the respective 
NOD mouse colony. However, based on recent evidence, dif-
ferences in proinflammatory polarization of innate immune 
cells and the local microenvironment between the NOD col-
onies of the two studies may in addition critically impinge on 
local T reg cell induction potential and thereby on outcomes 
of antigen-specific therapy and disease prevention efficacy 
(Kolb and von Herrath, 2017).
To broaden the window of subimmunogenic ligand ap-
plication and to increase robustness at a given antigen dose, 
we also had used a combination of insulin peptide applica-
tion together with the mTOR inhibitor everolimus (Daniel 
et al., 2011). This combination showed superior effects also 
on insulitis scores (Daniel et al., 2011). Approaches that can 
inhibit the signaling intermediates of T cell activation and/
or strategies that can impact β cell/metabolic function com-
bined with antigenic application therefore may function 
to strengthen the robustness of treatment outcomes (Kolb 
and von Herrath, 2017).
In summary, we previously concluded that (a) a strong ag-
onistic insulin mimetope induces stronger T cell proliferation 
and (b) when provided under appropriate subimmunogenic 
conditions is superior in inducing Foxp3+ T reg cells when 
compared with insulin B:9-23. We also found that (c) the com-
bination of the insulin-mimetope at subimmunogenic doses 
with the mTOR inhibitor everolimus is superior in inducing 
Foxp3+ T reg cells, that (d) at an appropriate subimmunogenic 
dose the insulin mimetope can prevent progression of diabetes 
development, and that (e) the combination of antigenic ther-
apy together with mTOR inhibition strengthens the tolerizing 
potential of T reg cell induction in NOD mice and reveals 
superior effects also on insulitis scores (Daniel et al., 2011).
Recent experiments by Bergman et al. (2017) confirm 
the notion (d) that individual subimmunogenic ligand dose 
identification for T reg cell conversion supports efficient tol-
erance induction and thereby can impact disease outcomes. 
In addition, their findings confirm our point that biological 
and environmental factors can impinge on antigenic dosing 
requirements and disease prevention efficacy. The other dis-
coveries and conclusions we reported were not addressed by 
these authors, but independently shown by several studies 
(Stadinski et al., 2010; Crawford et al., 2011) using different 
models and animal facilities.
More mechanistic studies are required to gain an im-
proved understanding of how antigen application for the effi-
cient and stable induction of T reg cells can be best achieved 
in the setting of T1D (Peakman, 2012). Combinatorial strate-
gies inhibiting the signaling intermediates of T cell activation 
might help to increase the robustness of tolerance induction 
to reduce T1D incidence (von Herrath et al., 2016).
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